Nancy L. Bartlett

Barnes-Jewish Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 43 papers. Top paper: “Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma”.

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Journal of Clinical Oncology(2020)10.1200/jco.20.00303

N/A

5.0DataRank · unranked

152 citations

Kieron Dunleavy, Jeremy S. Abramson, Bayard L. Powell, Brian K. Link, Prapti A. Patel +19 more

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Blood(2020)10.1182/blood.2019003277

N/A

3.7DataRank · unranked

95 citations

Mei‐Yin C. Polley, Michael V. Knopp, Nathan C. Hall, Lale Kostakoglu, Jun Zhang +14 more

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2405888

N/A

3.4DataRank · unranked

211 citations

Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens +42 more

Antibodies for the treatment of diffuse large cell lymphoma

Seminars in Oncology(2003)10.1016/s0093-7754(03)00251-3

N/A

1.7DataRank · unranked

18 citations

Nancy L. Bartlett, Kristie A. Blum

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4575

N/A

1.7DataRank · unranked

56 citations

Brian Hess, Veronika Bachanová, Nancy L. Bartlett, Melissa M. Berrien-Elliott, Ethan McClain +21 more

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

New England Journal of Medicine(2017)10.1056/nejmoa1707447

N/A

1.3DataRank · unranked

5812 citations

Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson +41 more

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Blood(2021)10.1182/blood.2021011894

N/A

1.2DataRank · unranked

35 citations

Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker‐Hapak, Amanda F. Cashen +15 more

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7506

N/A

1.1DataRank · unranked

29 citations

Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson +4 more

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

British Journal of Haematology(2021)10.1111/bjh.17527

N/A

0.808DataRank · unranked

217 citations

Krimo Bouabdallah, Javier Muñoz, Sophie De Guibert, Julie M. Vose, Nancy L. Bartlett +22 more

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

Blood Advances(2024)10.1182/bloodadvances.2023011657

N/A

0.691DataRank · unranked

26 citations

Sharmila Giri, Amy S. Ruppert, Susan M. Geyer, Scott E. Smith, Nimish Mohile +11 more

Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

Blood(2022)10.1182/blood.2022016534

N/A

0.673DataRank · unranked

88 citations

Kostiantyn Dreval, Daniela S. Gerhard, Laura K. Hilton, Jeremy S. Abramson, Richard F. Ambinder +63 more

Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin

Leukemia & Lymphoma(2012)10.3109/10428194.2012.676170

N/A

0.581DataRank · unranked

47 citations

Nancy L. Bartlett, Amanda Cashen, Joseph R. Berger, Nina D. Wagner-Johnston

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30067-3

N/A

0.510DataRank · unranked

29 citations

John P. Leonard, Thomas E. Witzig, Thomas M. Habermann, Kristie A. Blum, Nancy L. Bartlett +8 more

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

Blood Advances(2024)10.1182/bloodadvances.2022007792

N/A

0.497DataRank · unranked

13 citations

Michelle Becker‐Hapak, Kartik Singhal, David A. Russler‐Germain, Felix Frenkel, Erica K. Barnell +28 more

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

Hematological Oncology(2023)10.1002/hon.3163_5

N/A

0.464DataRank · unranked

21 citations

Michael LeBlanc, Sharon M. Castellino, Huilin Li, Sarah C. Rutherford, Andrew M. Evens +41 more

Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia

Journal of Geriatric Oncology(2023)10.1016/j.jgo.2023.101538

N/A

0.457DataRank · unranked

20 citations

Jennifer A. Woyach, Angela K. Ulrich, Veronique Marcotte, Ryan David Nipp, Daniel E. Lage +17 more

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7503

N/A

0.449DataRank · unranked

19 citations

Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir Parekh, David T. Yang +15 more

Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0140

N/A

0.416DataRank · unranked

15 citations

Bryan Fisk, Joshua F. McMichael, Matthew Mosior, Jennifer A. Foltz, Zachary L. Skidmore +26 more

ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia

Blood(2025)10.1182/blood.2024027460

N/A

0.345DataRank · unranked

9 citations

Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael Maris, Paolo Ghia +9 more

Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Cancers(2022)10.3390/cancers14122932

N/A

0.330DataRank · unranked

8 citations

Vanessa A. Sanders, Priyanka Pullarkat, Stephanie Teja, Amber Salter, Marcus P. Watkins +13 more

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

Cancer Medicine(2023)10.1002/cam4.5628

N/A

0.320DataRank · unranked

5 citations

Levi Pederson, Michael V. Knopp, David Poon, Jun Zhang, Brad S. Kahl +10 more

CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7507

N/A

0.312DataRank · unranked

7 citations

Travis Dockter, Amy S. Ruppert, Lale Kostakoglu, Heiko Schöder, Eric D. Hsi +8 more

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Blood Cancer Journal(2025)10.1038/s41408-025-01329-2

N/A

0.282DataRank · unranked

5 citations

Barbara Pro, Tim Illidge, Steven M. Horwitz, Lorenz Truemper, Swaminathan P. Iyer +22 more

Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

medRxiv(2021)10.1101/2021.06.25.21258374

N/A

0.269DataRank · unranked

5 citations

Matthew Mosior, Joshua McMichael, Zachary L. Skidmore, Eric J. Duncavage, Christopher A. Miller +24 more

21 | PROGNOSTIC VALUE OF CIRCULATING TUMOR DNA IN PATIENTS WITH ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA TREATED ON SWOG S1826

Hematological Oncology(2025)10.1002/hon.70093_21

N/A

0.254DataRank · unranked

4 citations

Marcin Kaszkowiak, Michael LeBlanc, Chip Stewart, Alex F. Herrera, J Castillo +18 more

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8042

N/A

0.241DataRank · unranked

4 citations

Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson +4 more

Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps7593

N/A

0.241DataRank · unranked

4 citations

Susan M. Geyer, Stefan K. Barta, Jennifer E. Amengual, Travis Dockter, Chadwick Wright +8 more

A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation(2020)10.1016/j.bbmt.2020.08.017

N/A

0.208DataRank · unranked

3 citations

Marcus P. Watkins, Fei Wan, Amanda F. Cashen, Nina D. Wagner‐Johnston, Meagan A. Jacoby +7 more

Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba7564

N/A

0.208DataRank · unranked

3 citations

Justin Kline, Aleksandr Lazaryan, Nancy L. Bartlett, Francisco J. Hernandez‐Ilizaliturri, Farrukh T. Awan +13 more

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma

Blood Advances(2025)10.1182/bloodadvances.2024015282

N/A

0.185DataRank · unranked

2 citations

Neha Mehta–Shah, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser +18 more

Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma

medRxiv(2022)10.1101/2022.01.06.22268805

N/A

0.104DataRank · unranked

1 citations

Felix Frenkel, Michelle Becker‐Hapak, Erica K. Barnell, Ethan McClain, Sweta Desai +27 more

20 | IMPACT OF EBV STATUS AND HISTOLOGY ON OUTCOMES WITH NIVOLUMAB‐AVD VERSUS Bv‐AVD IN PATIENTS ENROLLED ON SWOG S1826

Hematological Oncology(2025)10.1002/hon.70093_20

N/A

0.104DataRank · unranked

1 citations

H. Li, Alex F. Herrera, Anamarija M. Perry, Alexandra E. Kovach, Kelly Davison +13 more

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8038

N/A

0.104DataRank · unranked

1 citations

Jun Yin, Levi Pederson, Betsy LaPlant, Mazyar Shadman, Hongli Li +15 more

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

UNC Libraries(2020)10.17615/mbvm-5959

N/A

0DataRank · unranked

0 citations

Bruce D. Cheson, Matthew S. Davids, Kristie A. Blum, Sonali M. Smith, Steven I. Park +10 more

DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

Blood Cancer Discovery(2025)10.1158/2643-3230.bcd-24-0240

N/A

0DataRank · unranked

4 citations

Carlos A. García‐Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett +34 more

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Blood Advances(2023)10.1182/bloodadvances.2023010223

N/A

0DataRank · unranked

0 citations

Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani +10 more

Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma

Haematologica(2025)10.3324/haematol.2025.288946

N/A

0DataRank · unranked

0 citations

Thomas Ollila, Dai Chihara, Geoffrey Shouse, Natalie S. Grover, Reem Karmali +7 more

Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e20004

N/A

0DataRank · unranked

0 citations

Sumithra J. Mandrekar, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander +15 more

Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e13535

N/A

0DataRank · unranked

0 citations

Nicholas B. Larson, Timothy M. Pierpont, Nancy L. Bartlett, Andrew D. Zelenetz, Wyndham H. Wilson +5 more

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Leukemia & lymphoma/Leukemia and lymphoma(2025)10.1080/10428194.2025.2525982

N/A

0DataRank · unranked

2 citations

Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Patrick J. Stiff, Brian T. Hill +12 more

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303

Blood Advances(2023)10.1182/bloodadvances.2023010779

N/A

0DataRank · unranked

24 citations

Kilannin Krysiak, Cody A. Ramirez, Matthew Mosior, Marcus P. Watkins, Felicia Gomez +18 more

Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma

Blood Advances(2024)10.1182/bloodadvances.2023012090

N/A

0DataRank · unranked

2 citations

Jun Yin, Levi Pederson, Kristie A. Blum, Peter Martin, Sin‐Ho Jung +7 more

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Blood Advances(2022)10.1182/bloodadvances.2022009225

N/A

0DataRank · unranked

11 citations

Jeffrey M. Switchenko, Veronika Bachanová, James N. Gerson, Stefan K. Barta, Max J. Gordon +30 more